What records are connected here?
- Evidence lanes
- 3
- Source years
- 5
- Drugs@FDA applications
- 2
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trialsBrain, nerves and sleep
Trofinetide is a small synthetic molecule built from three amino-acid units, and the active ingredient in Daybue.1,2 FDA approved Daybue in 2023 for Rett syndrome in adults and children 2 years and older. The label states that how it works in Rett syndrome is unknown.1,2 In a 12-week randomized, placebo-controlled trial of 187 patients aged 5 to 20, it improved caregiver-rated symptoms and clinician ratings. The label states that most patients had diarrhea.1
| What it is | According to the chemical name in its label, trofinetide is built from glycine, a modified proline and glutamic acid. The label states that its mechanism in Rett syndrome is unknown.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Daybue with an original approval date of March 10, 2023. The cited label has no boxed warning.1,2 |
| Human evidence | One 12-week randomized, double-blind, placebo-controlled trial in 187 patients aged 5 to 20 with Rett syndrome, described in the label.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Trofinetide is a synthetic compound whose chemical name in the label describes three linked amino-acid units: glycine, a methylated proline and glutamic acid.1
In the United States it is the active ingredient of Daybue, from Acadia Pharmaceuticals, according to Drugs@FDA.2
The label states that the mechanism by which trofinetide has its effect in Rett syndrome is unknown.1
The label describes a 12-week randomized, double-blind, placebo-controlled trial (Study 1) in 187 patients aged 5 to 20 with Rett syndrome and a disease-causing MECP2 mutation; 93 received trofinetide and 94 placebo.1
Its two main measures were a caregiver-rated Rett syndrome behaviour questionnaire and a clinician’s global rating of improvement. Trofinetide showed a statistically significant difference from placebo on both at week 12, according to the label.1
The label reports that 85% of patients treated with it in Study 1 and longer-term studies had diarrhea.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes. Drugs@FDA lists Daybue, application NDA 217026, with an original approval date of March 10, 2023.2
The Daybue label cited here (DailyMed SPL version 12, published September 11, 2026) states that it is indicated for the treatment of Rett syndrome in adults and children 2 years of age and older.1
The label has no boxed warning and lists no contraindications. Its warnings cover diarrhea, weight loss, and vomiting followed by aspiration pneumonia.1
How it works: the label states that its mechanism in Rett syndrome is unknown.1
Its effects beyond 12 weeks of controlled comparison, since the trial described in the label lasted 12 weeks.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Trofinetide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Trofinetide are a bounded selection, not every registration or paper about Trofinetide. For the years before Trofinetide was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Trofinetide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Trofinetide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Daybue for Rett syndrome. A 12-week randomized, placebo-controlled trial of 187 patients described in the label found improvement on caregiver and clinician ratings. The label states that its mechanism is unknown and that most patients had diarrhea.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Daybue for Rett syndrome. A 12-week randomized, placebo-controlled trial of 187 patients described in the label found improvement on caregiver and clinician ratings. The label states that its mechanism is unknown and that most patients had diarrhea.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date October 1, 2026
Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide.↗Added to PeptideScanner November 15, 2026Literature metadata · added November 15, 2026
Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide.↗Source date October 1, 2026Literature metadata · added November 15, 2026
Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States.↗Source date September 26, 2026Literature metadata · added November 15, 2026
Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States.↗Source date August 28, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
3 of 3 selected trial records include at least one phase value; 3 of 3 include a status value in the retained structured contract.
20 of 20 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT02715115 at 2026-11-15T21:57:22.404Z. Its registry update date was 2020-08-14, and PeptideScanner's reviewed identity mapping was trofinetide.
PeptideScanner retained ClinicalTrials.gov record NCT04181723 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-08, and PeptideScanner's reviewed identity mapping was trofinetide.
PeptideScanner retained ClinicalTrials.gov record NCT04279314 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-11, and PeptideScanner's reviewed identity mapping was trofinetide.
20 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span August 14, 2020 to October 1, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 42377739 in Advances in therapy as Journal Article, with publication-date metadata of 2026-06-30 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42294489 in Journal of health economics and outcomes research as Journal Article, with publication-date metadata of 2026-06-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42577214 in Frontiers in neurology as Journal Article, with publication-date metadata of 2026-07-27 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39692837 in Advances in therapy as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-12-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42530159 in Journal of computational chemistry as Journal Article, with publication-date metadata of 2026-08-05 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42563928 in Annals of the Child Neurology Society as Journal Article, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42083929 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2026 (year precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41850142 in Bioorganic & medicinal chemistry as Journal Article, with publication-date metadata of 2026-03-14 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42287113 in Journal of medical economics as Journal Article, with publication-date metadata of 2026-06-13 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39395401 in Med (New York, N.Y.) as Journal Article, Comment, with publication-date metadata of 2024-10-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 38378975 in Advances in therapy as Clinical Trial, Phase III, Journal Article, with publication-date metadata of 2024-02-20 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 219884 with status AP dated 2025-12-11, and names trofinetide among the application record's active ingredients.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026